Thomas Malley
CIK 1403322 · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KNSA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CLARENDON HOUSE, 2 CHURCH STREET
HAMILTON, D0 HM11
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KURA | Director | 149,557 | $9.88 | $1.48M | $975.0K | 14 | 2026-06-04 |
| KNSA | Director | 87,312 | $81.18 | $7.09M | -$5.86M | 11 | 2026-06-02 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 46,696 | $184.71 | $8.63M | $960.0K | 8 | 2023-06-20 |
| Tempest Therapeutics, Inc. (OVAS) Delisted | Director | 13,665 | — | — | $1.89M | 16 | 2017-07-05 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 0 | — | — | $0 | 6 | 2015-06-23 |
| PBYI | Director | 156,551 | $11.32 | $1.77M | $160.0K | 4 | 2014-12-16 |
| Cougar Biotechnology, Inc. (CGRB) Delisted | Director | 0 | — | — | $0 | 2 | 2009-07-07 |
Recent Filings · Page 2 of 8
73 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-07 | KURA | Grant (A) | — | $0 | EDGAR |
| 2023-07-03 | KNSA | Exer (M) | +5,000 | $0 | EDGAR |
| 2023-06-21 | KURA | Buy (P) | +50,000 | $575.0K | EDGAR |
| 2023-06-20 | BeOne Medicines Ltd. (BGNE) Delisted | Grant (A) | +12,922 | $0 | EDGAR |
| 2023-06-08 | KNSA | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | KURA | Grant (A) | — | $0 | EDGAR |
| 2022-06-30 | KNSA | Grant (A) | — | $0 | EDGAR |
| 2022-06-24 | BeOne Medicines Ltd. (BGNE) Delisted | Grant (A) | +16,692 | $0 | EDGAR |
| 2022-06-23 | KURA | Grant (A) | — | $0 | EDGAR |
| 2021-06-30 | KNSA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.